Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binary status seric values, identifying one third of patients with worst prognostic. Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, …

oxaliplatin
colorectal adenocarcinoma
bevacizumab
folfiri regimen
metastatic colorectal adenocarcinoma
  • 6 views
  • 03 Aug, 2021
  • 13 locations
DOT HeartMate 3 Study

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

  • 0 views
  • 21 Apr, 2022
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

tumor burden
bendamustine
rituximab
platelet count
lenalidomide
  • 58 views
  • 04 Oct, 2022
  • 28 locations
  • 0 views
  • 25 Oct, 2022
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment naïve, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, …

eculizumab
complement inhibitor
reticulocyte count
platelet count
ravulizumab
  • 41 views
  • 07 Oct, 2022
  • 8 locations
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5)

Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for resectability. In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively …

metastasis
folfiri regimen
bevacizumab
liver surgery
cancer
  • 249 views
  • 07 Apr, 2022
  • 50 locations
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. (DOBL)

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement …

hodgkin's disease
cancer
chop regimen
diffuse large b-cell lymphoma
b-cell lymphoma
  • 83 views
  • 25 Feb, 2022
  • 1 location
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

-risk cohorts including symptomatic brain metastases or liver metastases with elevated lactate dehydrogenase (LDH) or bulky systemic disease burden.

nivolumab
ipilimumab
tumor cells
brain metastases
braf inhibitor
  • 5 views
  • 13 Apr, 2022
  • 1 location
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

The primary objective of the study is: To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of

flow cytometry
eculizumab
ravulizumab
lactate dehydrogenase
fatigue
  • 0 views
  • 25 Mar, 2022
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

elevations of lactate dehydrogenase (LDH), and associated multi-organ dysfunction from invasive or obstructive processes RS occurs in 2-10% of CLL patients with an incidence rate of 0.5% per year. The

  • 0 views
  • 15 Dec, 2021
  • 4 locations